Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.

Cha Len LeeMattia CremonaAngela FarrellyJulie A WorkmanSean KennedyRazia AslamAoife CarrStephen MaddenBrian O'NeillBryan T HennessySinead Toomey

Published in: Cancer biology & therapy (2023)

This study shows that the combination of Palbociclib and Gedatolisib has synergistic anti-proliferative effects in both wild-type and mutated CRC cell lines. Separately, the phosphorylation of S6rp may be a promising biomarker of responsiveness to this combination.

Keyphrases

wild type
metastatic breast cancer
cell cycle
signaling pathway
cell proliferation
cell therapy
bone marrow
pi k akt
mesenchymal stem cells
cancer therapy